Dynamics of biosimilar uptake in emerging markets
- 22 May 2022
- journal article
- research article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 22 (6) , 679-688
Abstract
Globally, biosimilars are expected to play a key role in lowering healthcare costs and providing increased patient access to biological therapies. Given this, and in line with the European Union an...Keywords
Funding Information
- Department of Biotechnology, Ministry of Science and Technology (BT/COE/34/SP15097/2015)
This publication has 43 references indexed in Scilit:
- Chronic Noncommunicable Diseases in 6 Low- and Middle-Income Countries: Findings From Wave 1 of the World Health Organization's Study on Global Ageing and Adult Health (SAGE)American Journal of Epidemiology, 2017
- Key drivers for market penetration of biosimilars in EuropeJournal of Market Access & Health Policy, 2017
- How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European CountriesApplied Health Economics and Health Policy, 2017
- Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty PhysiciansAdvances in Therapy, 2016
- Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatologyRheumatology International, 2016
- Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologistsClinical Rheumatology, 2015
- Biosimilars in Oncology: From Development to Clinical PracticeSeminars in Oncology, 2014
- Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countriesHealth Policy and Planning, 2014
- Global cancer transitions according to the Human Development Index (2008–2030): a population-based studyThe Lancet Oncology, 2012
- Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countriesThe Lancet, 2010